Canaccord Genuity analyst Cecilia Furlong maintained a Buy rating on Vapotherm (NYSE:VAPO) Inc on Wednesday, setting a price target of $54, which is approximately 2.00% above the present share price of $52.94.
Furlong expects Vapotherm Inc to post earnings per share (EPS) of -$0.66 for the third quarter of 2020.
The current consensus among 2 TipRanks analysts is for a Moderate Buy rating of shares in Vapotherm, with an average price target of $53.5.
The analysts price targets range from a high of $54 to a low of $53.
In its latest earnings report, released on 03/31/2020, the company reported a quarterly revenue of $19.12 million and a net profit of -$12.71 million. The company's market cap is $1.13 billion.
According to TipRanks.com, Canaccord Genuity analyst Cecilia Furlong is currently ranked with 3 stars on a 0-5 stars ranking scale, with an average return of 9.2% and a 55.56% success rate.
Vapotherm, Inc. is a medical technology company, which engages in the development and commercialization of medical devices for patients suffering from respiratory distress. It offers Hi-VNI Technology, a product which delivers noninvasive ventilator support by providing heated, humidified, and oxygenated air at a high velocity to patients through a small-bore nasal interface. Its products include Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, Precision Flow Heliox, Vapotherm Transfer Unit 2.0, Q50 compressor, Disposable Patient Circuit, Nitric Oxidie Disposable Patient Circuit, Nasal Cannulas, Tracheostomy Adapter and Aerogen Adapter. The company was founded by William F. Niland, Jun Cortez, and William Cirksena in 1998 and is headquartered in Exeter, NH.